A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides

Yuhong Du, Emory University
Haian Fu, Emory University

Journal Title: Current chemical genomics
Volume: Volume 2
Publisher: Bentham Open | 2008, Pages 40-47
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.2174/1875397300802010040
Permanent URL: http://pid.emory.edu/ark:/25593/fkjg6

Final published version:

Copyright information:
© Du et al.; Licensee Bentham Open. This is an Open Access work distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License (http://creativecommons.org/licenses/by-nc/3.0/).

Accessed January 22, 2018 7:07 AM EST
A Homogenous Luminescent Proximity Assay for 14-3-3 Interactions with Both Phosphorylated and Nonphosphorylated Client Peptides

Yuhong Du1,3, Fadlo R. Khuri2 and Haian Fu*,1,2,3

1Departments of Pharmacology; 2Hematology and Medical Oncology, Emory University School of Medicine and 3Emory Chemical Biology Discovery Center, Atlanta, GA 30322, USA

Abstract: The 14-3-3 proteins are a family of dimeric eukaryotic proteins that mediate both phosphorylation-dependent and -independent protein-protein interactions. Through these interactions, 14-3-3 proteins participate in the regulation of a wide range of cellular processes, including cell proliferation, cell cycle progression, and apoptosis. Because of their fundamental importance, 14-3-3 proteins have also been implicated in a variety of diseases, including cancer and neurodegenerative disorders. In order to monitor 14-3-3/client protein interactions for the discovery of small molecule 14-3-3 modulators, we have designed and optimized 14-3-3 protein binding assays based on the amplified luminescent proximity homogeneous assay (AlphaScreen) technology. Using the interaction of 14-3-3 with a phosphorylated Raf-1 peptide and a nonphosphorylated R18 peptide as model systems, we have established homogenous “add-and-measure” high-throughput screening assays. Both assays achieved robust performance with S/B ratios above 7 and Z’ factors above 0.7. Application of the known antagonistic peptides in our studies further validated the assay for screening of chemical compound libraries to identify small molecules that can modulate 14-3-3 protein-protein interactions.

Keywords: 14-3-3, AlphaScreen, protein-protein interaction, HTS.

INTRODUCTION

The 14-3-3 proteins are a family of eukaryotic regulatory proteins that can recognize phosphoserine/threonine (pSer/Thr)-containing motifs utilized by a variety of signal transduction pathways [1-5]. 14-3-3 can directly bind pSer or pThr in specific sequence contexts (Fig. 1) [6, 7]. Sequences around pS259 and pS621 in Raf-1 are well studied examples. This phosphorylation-dictated interaction allows 14-3-3 proteins to bind a multitude of functionally diverse molecules, including kinases, phosphatases, transmembrane receptors, and transcription factors [1, 5, 8]. In addition, 14-3-3 has been shown to bind to client proteins in a phosphorylation-independent manner. For example, 14-3-3 can activate the Exoenzyme S ADP-ribosyltransferase, a prokaryotic protein factor secreted by Pseudomonas aeruginosa [9]. The identification of high affinity peptides as 14-3-3 binding sequences, such as R18, by phage display technology further validates this mode of nonphosphorylation-dependent 14-3-3 interaction [10]. Through these interactions, 14-3-3 proteins participate in the regulation of a wide range of vital cellular processes, including cell proliferation, cell cycle progression, and apoptosis, as well as in a number of pathophysiological conditions, such as cancer and neurodegenerative diseases. Thus, understanding the mechanisms that govern 14-3-3/client protein interactions will provide critical insight into the control of intracellular signal transduction. Availability of 14-3-3 modulators is expected to greatly facilitate our mechanistic investigation of 14-3-3 functions. These 14-3-3 modulators may become leads for potential therapeutic development.

Fig. (1). 14-3-3 binds phosphorylated Ser/Thr motifs with RSxpS/TxP as a prototype. It plays an important role in multiple signaling pathways.

In order to identify small molecule 14-3-3 modulators, fluorescent polarization (FP) assays have been reported [11, 12]. The FP-based assays are widely used for high-throughput screening (HTS) due to their simplicity and sensitivity. However, they are prone to interference by fluorescent compounds and are not applicable for protein-protein interactions. Here we describe an alternative HTS assay format for 14-3-3 proteins based on the AlphaScreen (Amplified Luminescent Proximity Homogenous Assay) technology.
[13, 14]. AlphaScreen offers a bead-based, non-radioactive homogeneous assay that can be adapted to small volumes in a microplate format. It can be used either as a primary HTS assay or as a confirmative assay and has added value by allowing the detection of interactions between two full-length proteins. Using both phosphorylated and nonphosphorylated client targets of 14-3-3 proteins, we have designed and tested AlphaScreen-based 14-3-3 assays for HTS. These assays have been further optimized and validated with known peptide inhibitors for the screening of small molecule 14-3-3 inhibitors.

**EXPERIMENTAL PROCEDURES**

**Purification of Recombinant 14-3-3γ and GST-R18 Proteins**

Recombinant 14-3-3γ protein was expressed in *Escherichia coli* strain BL21 (DE3) as a glutathione S-transferase (GST)-tagged or hexahistidine (His)-tagged product as previously described [11]. Similarly, GST-R18 fusion protein was overexpressed in *E. coli*. His-14-3-3 protein was purified by a Ni²⁺-charged His-binding column (Novagen) as previously described [9], and used for biontinylation. GST-14-3-3γ and GST-R18 proteins were purified using a glutathione-conjugated Sepharose column (GE Healthcare) [11]. The isolated protein fractions containing 14-3-3γ were desalted using a PD-10 desalting column (GE Healthcare) equilibrated in HEPES buffer. The purified proteins were stored at -20°C before use.

**Basic Assay Development**

The AlphaScreen binding assay was carried out in 384-well, white Proxiplates (PerkinElmer, Boston, MA) in a total volume of 20 μl. The AlphaScreen GST detection kit was from PerkinElmer Life Science.

To test the feasibility of the assay platform, we detected the binding of 14-3-3γ to R18 peptide. R18 (PHCVPRDLSWLDLEANMCLP) is an unphosphorylated peptide derived from phage display which exhibits a high affinity for 14-3-3 proteins [10]. The AlphaScreen donor beads were supplied as streptavidin-coated, and the acceptor beads were conjugated to an anti-GST antibody. Biotinylated 14-3-3γ protein was generated using EZ-Link™ sulfo-NHS-LC-biotin (Pierce) with purified His-14-3-3γ protein and GST-R18. The binding experiments were conducted similarly as described above for biotin-14-3-3γ protein and GST-R18.

**Peptide Competition Assays**

In order to verify the specificity of the 14-3-3 binding assay, two untagged antagonist peptides of 14-3-3 proteins, R18 and a phosphorylated pS967-ASK1-peptide, were used to test their ability to displace the GST-R18 or biotin-pS259-Raf from 14-3-3 proteins. An R18 mutant peptide and a nonphosphorylated ASK1 peptide were used as controls. Peptides were synthesized at the Emory Microchemistry Facility and dissolved in HEPES buffer as stocks. Within each binding experiment, dose-dependent competition was carried out with serial dilutions of peptides, prepared in HEPES buffer. In a 384-well plate, 0.5 μl of each diluted untagged peptide was added to 4.5 μl of each assay mixture (biotin-14-3-3γ and GST-R18 or GST-14-3-3γ and biotin-pS259-Raf). For each assay, background (one binding component only) and control (without competition peptide) samples were included in each assay plate. The competitive effect of the peptides on binding was expressed as a percentage of control Alpha signal as the following:

\[
\% \text{ of control} = \left( \frac{\text{Alpha signal (peptide)} - \text{Alpha signal (background)}}{\text{Alpha signal (control) - Alpha signal (background)}} \right) \times 100
\]

Data were plotted against log₁₀ value of peptide concentrations and analyzed using Prism 4.0 software (Graphpad Software, San Diego, CA). IC₅₀ values were determined by non-linear curve fitting as the concentrations of the peptides at which 50% of control Alpha signal was inhibited.

**High-Throughput Screening Assay Performance**

To monitor assay sensitivity, signal-to-background (S/B) ratios were calculated by the following equation:

\[
S/B = \frac{\text{mean signal binding}}{\text{mean background}}
\]

To evaluate the quality and suitability of the 14-3-3 binding assay using AlphaScreen for HTS, we determined the Z‘ factor [15]:

\[
Z’ = 1 - \frac{3 \times \text{SD of control} + 3 \times \text{SD of background}}{\text{mean of control} - \text{mean of background}}
\]

To monitor the robustness and reproducibility of the 384-well HTS format, the means of both background and control Alpha signal from each assay plate were obtained and analyzed by a scatter plot.

**RESULTS AND DISCUSSION**

AlphaScreen technology provides a proximity-dependent homogeneous assay format for studying molecular interactions [13, 14]. This assay system contains two beads, a “donor” bead and an “acceptor” bead. Donor beads contain the
photosensitizer phthalocyanine, which upon illumination at 680 nm converts ambient oxygen to an excited form of oxygen, singlet oxygen. If an acceptor bead is within the energy diffusion range (< 200 nm) in solution, energy is transferred from the singlet oxygen to thioxene derivatives within the acceptor bead, resulting in light production at 520-620 nm (Fig. 2). The proximity of these two beads can be induced by interaction of two binding components that are coupled to the beads. In the AlphaScreen system employed in our study, the donor beads were coated with streptavidin and acceptor beads were conjugated to anti-GST antibody. Utilizing the AlphaScreen technology, we have designed two assay formats for 14-3-3 binding studies. One assay was used for monitoring the association of 14-3-3 with the non-phosphorylated binding peptide R18 (Fig. 2A), while the other assay was used for detecting the interaction of 14-3-3 with a phosphorylated peptide derived from the well-studied client protein Raf-1 (Fig. 2B).

**Fig. (2).** Design of AlphaScreen-based 14-3-3 binding assays. (A) Biotin-14-3-3 proteins are coupled to streptavidin-coated donor beads (D) while GST-R18 is attached to anti-GST antibody-coated acceptor beads (A). (B) Biotinylated pS259-Raf-1 peptides are coupled to streptavidin-coated donor beads while GST-14-3-3 proteins are attached to acceptor beads with coated anti-GST antibodies. Interaction of 14-3-3 with R18 or pS259-Raf-1 results in generation of luminescence signals at the indicated wavelength.

**Interaction of 14-3-3 with R18**

To test the feasibility of using the AlphaScreen technology for monitoring the interaction of 14-3-3 with its client proteins, we utilized the well-established association of 14-3-3 with a high affinity peptide, R18, as a model system. Examinations by mutational and structural approaches have conclusively established that R18 docks in the ligand binding site of 14-3-3 that is also used by natural client proteins [10, 16]. Functionally, R18 can effectively compete with other natural proteins for the binding of 14-3-3 proteins [17]. Thus, the 14-3-3/R18 interaction was utilized to provide a proof-of-concept for the development of an HTS assay with the AlphaScreen technology platform.

The AlphaScreen requires the coupling of test protein components onto specific donor and acceptor beads. Accordingly, we generated biotinylated His-14-3-3γ protein for coupling to the streptavidin-coated donor beads (Fig. 2). To ensure that the biotinylation did not compromise the binding activity of 14-3-3 proteins, we examined the interaction of the biotin-14-3-3γ protein with a Raf-1 peptide using a FP assay [11]. Biotinylation appeared to have no obvious effect on the binding properties of 14-3-3γ with a K_D (0.76 μM) comparable to nonbiotinylated 14-3-3 (K_D of 0.42 μM [11]; Fig. 3A). For generating the corresponding acceptor beads, a GST-tagged R18 protein-peptide fusion was purified for coupling to the anti-GST antibody-coated beads. We used the R18 fusion protein in order to place the 14-3-3 recognition sequence within the context of a full length protein to mimic the situation in natural 14-3-3 client proteins. Our previous studies demonstrated that the fusion of GST had no detectable effect on the efficacy of R18 for 14-3-3 binding [10]. These reagents were then added to the reaction in different sequences or combinations before the Alpha luminescence signal was recorded. As shown in Fig. (3B), when biotin-14-3-3γ proteins (5 nM, 10 nM, or 30 nM) were incubated with the donor and acceptor beads in the absence of GST-R18, only a low background Alpha signal (~2,000 counts) was generated. However, the addition of increasing concentrations of GST-R18 (5 nM to 500 nM) to the biotin-14-3-3γ solutions (5 nM or 10 nM) induced the robust production of Alpha signal in a dose-dependent manner. The specific Alpha signal, calculated by subtracting the background counts, approached approximately 46,000 counts with 5 nM of biotin-14-3-3γ and 10 nM of GST-R18. The S/B ratio of the assay reached beyond 10 under the conditions tested, which defines an excellent assay window (Fig. 3C). Further increases in the GST-R18 concentration beyond 100 nM or the biotin-14-3-3 protein concentration beyond 30 nM resulted in a decrease in Alpha signal and S/B ratio. This “hooking effect”, an effect common to many immunoassays relying on antibody recognition and binding of target molecules, is likely due to the saturation of available binding sites on one or both of the AlphaScreen beads [18]. It has been shown that Alpha signal increases with increasing target molecule concentrations up to a point, after which the target molecules will become inhibitory to the production of Alpha signals [19, 20]. These studies suggest that the AlphaScreen assay platform can be used to monitor the interaction of 14-3-3 with its binding partners.

To evaluate the quality and suitability of the AlphaScreen assay for HTS in a 384-well microplate format, the Z’ factors were determined. The Z’ factor incorporates the dynamic assay range and the assay variability into a single metric, and is a parameter for the quality of the assay itself without test compounds [21]. The Z’-factor is widely utilized for quality assessment in assay development and optimization. Assays with Z’ factors between 0.5 and 1 (the maximum) are considered of high quality and suitable for automation and the subsequent screening. As shown in Fig. (3D), when biotin-14-3-3γ at a concentration of 5 nM or 10 nM was incubated with GST-R18 (5 nM, 10 nM, or 30 nM), the calculated Z’ values were all above 0.7, supporting a robust assay format. Thus, this AlphaScreen assay for the 14-3-3 and R18 interaction can be further developed for HTS of 14-3-3 modulators.
Fig. (3). AlphaScreen assay for measuring the interaction of 14-3-3 with R18. (A) Biotinylation has no effect on the ligand binding capability of His-14-3-3 proteins. Binding of biotin-14-3-3 to pS259-Raf-1 peptide was determined by FP assay [11]. Biotin-14-3-3 proteins were incubated with a TMR-pS259-Raf peptide (1 nM) at RT for 30 min and the FP signal [expressed in millipolarization units (mP)] was read with an Analyst HT reader (Molecular Devices). Specific binding (mP) was obtained by subtracting free peptide tracer values from values recorded in the presence of 14-3-3 proteins. (B) Interaction of biotin-14-3-3 with GST-R18 generates an Alpha luminescence signal. Increasing concentrations of GST-R18 protein were incubated with biotin-14-3-3 protein at RT for 30 min. Donor and acceptor beads were added with an interval of 30 min. The plate was assayed using an EnVision multilabel plate reader after 1.5 hr incubation at room temperature. Data are expressed as mean ± SD from triplicate samples. (C) S/B ratios of the 14-3-3/R18 AlphaScreen assay. (D) Z’ values of the assay.

Fig. (4). Competition with untagged peptide antagonists, R18 and pS967-ASK1, in the 14-3-3/R18 AlphaScreen assay. Biotin-14-3-3γ (5 nM) and GST-R18 (15 nM) were incubated with increasing concentrations of untagged antagonists at RT for 1 hr. After incubation for 1.5 hr upon addition of donor and acceptor beads, Alpha signals were recorded. (A) Competition with the R18 peptide or the mutated control (R18Lys) peptide. (B) Competition with pS967-ASK1 or the non-phosphorylated control (ASK1) peptide. The y-axis of the graph represents the percentage of the control. The control is defined by maximal Alpha signal obtained in the absence of any inhibitor with background counts subtracted. Data are expressed as means ± SD from triplicate determinations.

To validate the AlphaScreen assay for the discovery of 14-3-3 inhibitors, we tested inhibition of the interaction of 14-3-3 with the R18 by two untagged antagonist peptides: an R18 peptide and an ASK1 peptide, pS967-ASK1. The untagged R18 and pS967-ASK1 peptides are expected to compete with GST-R18 for the binding of 14-3-3 proteins. Indeed, incubation of increasing concentrations of untagged R18 peptide with biotin-14-3-3γ and GST-R18 led to a dose-dependent decrease in Alpha signal with an IC₅₀ value of 28 ± 1.1 nM (Fig. 4A). On the other hand, untagged
R18Lys, a R18 peptide with a mutated 14-3-3 binding residue, failed to displace GST-R18 from the 14-3-3 protein, supporting a specific effect of the R18 competitor. Many 14-3-3 client proteins, including ASK1, require phosphorylation to mediate the binding to 14-3-3 proteins. The pS967-ASK1 peptide is a 14-3-3 binding peptide that contains phosphorylated Ser-967 and its surrounding sequence within the ASK1 protein [21, 22]. As shown in Fig. (4B), the free pS967-ASK1 peptide competed with the binding of GST-R18 to 14-3-3γ, resulting in a dose-dependent decrease in Alpha signal with an IC50 value of 549.4 ± 1.1 nM. The same ASK1 peptide without phosphorylation, however, had no effect on the Alpha signal generated from the 14-3-3 binding to R18 (Fig. 4B). These results are consistent with reported interactions of 14-3-3 with phosphorylated client peptides [6, 7]. Thus, small molecules that compete for the binding of R18 to 14-3-3 proteins can be revealed in the AlphaScreen-based assay platform.

**Interaction of 14-3-3 with a Raf-1 Peptide**

With the establishment of a general platform for monitoring 14-3-3 interactions, we extended our study to examine the utility of the AlphaScreen technology for the binding of 14-3-3 to a phosphorylated peptide derived from Raf-1, a mitogen-activated protein kinase regulator. It has been well-established that phosphorylation of Raf-1 at Ser-259 induces its association with the 14-3-3 proteins, which plays a critical role in Raf-1-mediated cell signaling [6, 8, 23-25]. To test the 14-3-3/Raf-1 interaction in the AlphaScreen system, we generated a biotinylated Raf peptide, pS259-Raf-1, for coupling to streptavidin-coated donor beads. 14-3-3γ was produced and purified as a GST-tagged fusion protein for coupling to the GST-antibody coated acceptor beads. The interaction of biotin-pS259-Raf-1 peptide with GST-14-3-3γ would bring donor and acceptor beads together and induce the production of Alpha signal (Fig. 2B). Indeed, mixing increasing concentrations of GST-14-3-3γ and biotin-pS259-Raf-1 with both beads resulted in a dose-dependent increase in Alpha signal (Fig. 5A). When incubated with 30 or 100 nM of biotin-pS259-Raf-1, the S/B ratio significantly increased with increasing concentration of 14-3-3 proteins (Fig. 5B). The calculated Z’ factors were above 0.6 when 100 nM of biotin-pS259-Raf-1 was incubated with increasing concentrations of GST-14-3-3 protein (Fig. 5C).

---

**Fig. (5).** AlphaScreen assay for measuring the interaction of 14-3-3γ with pS259-Raf-1. Experiments were performed as described in the legend to Fig. (4) using 100 nM of GST-14-3-3γ and 100 nM of biotin-pS259-Raf-1 peptide. For (A), (D), and (E), data are expressed as means ± SD from triplicate determinations. (A) Increasing concentrations of GST-14-3-3γ protein were incubated with biotin-pS-259-Raf peptide at RT for 30 min. Donor and acceptor beads were added with an interval of 30 min. Results were recorded after 3 hr of incubation at RT. (B) The S/B ratios of the assay. (C) The Z’ factor of the assay. (D) Competition with the R18 peptide or its mutant peptide, R18Lys, in the 14-3-3γ/pS259-Raf-1 AlphaScreen assay. (E) Competition assay using the pS967-ASK1 or its non-phosphorylated ASK1 control peptide.
tors reached 0.9 when 30 or 100 nM of 14-3-3 was used, indicating a robust assay performance.

To validate this assay for the screening of 14-3-3 inhibitors, two untagged 14-3-3 peptide antagonists were tested for inhibition of the interaction of 14-3-3 with Raf-1. R18 or pS967-ASK1 antagonist peptides were incubated with GST-14-3-3γ (100 nM) and biotin-pS259-Raf-1 peptide (100 nM), and Alpha signals were recorded. These two 14-3-3 antagonists effectively competed with the 14-3-3/Raf-1 binding as shown by decreased Alpha signal with the increasing concentrations of R18 or pS967-ASK1 peptide (Figs. 5D and 4E). Importantly, the R18Lys or non-phosphorylated ASK1 control peptides showed no effect in this assay. The calculated IC50 values for the R18 peptide was 35.7 ± 1.1 nM and for the pS967-ASK1 peptide was 534.9 ± 1.1 nM, which is consistent with the results obtained in the 14-3-3/R18 interaction assay (Fig. 4).

**HTS Assay Validation**

One potential use of a homogeneous assay for 14-3-3 binding is to carry out HTS of chemical libraries for the identification of small molecule 14-3-3 inhibitors. In order to evaluate the suitability of the AlphaScreen-based 14-3-3 assays for HTS, a series of experiments were performed.

First, the dimethyl sulfoxide (DMSO) tolerance level of the assay was evaluated. DMSO is a common solvent used in dissolving chemical compounds. To determine the effect of DMSO on the AlphaScreen based 14-3-3 assay, experiments were performed in the presence of varying amounts of DMSO. As shown in Fig. (6A), the Alpha signals for the binding of biotin-14-3-3γ (5 nM) to GST-R18 (15 nM) were not significantly altered in the presence of up to 5% DMSO. Then, we determined the assay stability by performing competition experiments and recording the AlphaScreen luminescence signal over time. As shown in Fig. (6B), the addition of untagged R18 peptide to the reaction containing biotin-14-3-3γ, GST-R18, and the donor/acceptor beads, decreased the Alpha luminescence signals in a dose-dependent manner. No significant difference was noticed when the result was recorded either at 1.5 hr or 16 hr after mixing the reaction components. Similar IC50 values were obtained with these two time points (28.0 ± 1.1 nM for 1.5 hr and 33.6 ± 1.1 nM for 16 hr). These results suggest that the AlphaScreen assay for HTS of 14-3-3 inhibitors is stable over a time period of at least 16 hr, which allows the reading of more than 120 microplates (384-well) with the Envision plate reader. Finally, we evaluated parameters for HTS performance and assay consistency by testing well-to-well and plate-to-plate variation of the binding assay in a total volume of 20 μl. Each reaction contained 5 nM of biotin-14-3-3 and 15 nM of GST-R18 as in Fig. (3). The Z’ factor and S/B ratio of reactions from ten individual plates were recorded and compared (Figs. 7A and 7B). Among these 10 plates, the average value for Z’ was 0.73 with a standard deviation of 0.06 and the average S/B ratio was 10.6 with a standard deviation of 2.4, indicating the robustness and suitability of this assay for automation. We further evaluated the assay consistency by performing the R18 peptide competition assay with the biotin-14-3-3γ/GST-R18 interaction pair on different days. As shown in Fig. (7C), the dose-response curves obtained from measurements in two different plates at two different days gave rise to similar IC50 values (27.3 nM and 43.2 nM, respectively), demonstrating high consistency of the AlphaScreen assays.

![Fig. (6). Evaluation of the DMSO tolerance and stability of the 14-3-3 AlphaScreen assay.](image)

**CONCLUSIONS**

We have developed and optimized a HTS assay in a 384-well format by using the AlphaScreen technology for the detection of 14-3-3 protein interaction with both phosphorylated and nonphosphorylated client peptides. Experimental conditions for both 14-3-3/R18 and 14-3-3/pS259-Raf-1 pairs have been established that gave rise to a robust assay performance with S/B ratio above 7 and Z’ factors above 0.7. Further validation experiments provided evidence that the competitive 14-3-3 binding assays using AlphaScreen can be used for HTS for the screening of 14-3-3/client peptide interaction inhibitors. These assays utilize a small amount of test proteins (low nM) in a low volume (20 μl), which makes them particularly suited for HTS. It is expected that this assay is also applicable for monitoring the interaction of 14-3-3...
The binding assay was performed essentially as described in Fig. (4), using biotin-14-3-3y (5 nM) and GST-R18 (15 nM) and 10 assay plates (384-well). (A) Z′ factor for the 14-3-3 AlphaScreen assay. The Z′ values across the 10 plates were consistently higher than 0.7. (B) The S/B values, calculated for each of the 10 plates, were all above 7. (C) Day to day variation. Day to day precision was assessed by comparison of 2 representative dose-response competition curves of R18 peptide which were performed on 2 different days. Results are shown as a percentage of control Alpha signal (obtained in the absence of inhibitor) after subtracting the background (biotin-14-3-3 only). Data are expressed as means ± SD from triplicate determinations.

3 with its full length client proteins in future HTS campaigns.

ACKNOWLEDGEMENTS

We are grateful to Jeff Pfohl and Jeff Selander from PerkinElmer for valuable suggestions and to Lisa M. Cockrell for critical reading of the manuscript. We also thank members of the Fu lab for assistance. This work was supported in part by National Institutes of Health Grant GM60033, R03MH076385, U54HG003918 and P01CA116676. Y.D. is a recipient of the Emory Drug Development and Pharmacogenomics Academy Research Fellowship and an Emory Head and Neck Cancer SPORE Career development award (P50 CA128613). F.R.K. and H.F. are Georgia Cancer Coalition Distinguished Cancer Scholars and H.F. is a Georgia Research Alliance Distinguished Investigator.

REFERENCES

[18] PerkinElmer LaAS. A practical guide to working with AlphaScreen 2004 [cited; Available from: http://las.perkinelmer.com/ Content/Manuals/GDE_AlphaScreenPracticalGuide.pdf]

